Phase 3 lung cancer trial misses survival endpoint
A randomized phase 3 trial designed to evaluate tiragolumab plus atezolizumab for certain patients with advanced lung cancer failed to meet its co-primary endpoint of OS, according to the agents’ manufacturer
Tiragolumab (Genentech/Roche) is an immunotherapy designed to bind to TIGIT, a protein receptor on immune cells. Atezolizumab (Tecentriq, Genentech/Roche) is an anti-PD-L1 therapy.
The global double-blind SKYSCRAPER-01 study included 534 patients with PD-L1-high locally advanced unresectable or metastatic non-small cell lung cancer.
Researchers randomly assigned patients 1:1 to first-line treatment with the combination or atezolizumab alone.
Treatment continued until disease progression, loss of clinical benefit or unacceptable toxicity.
In 2022, Genentech announced the trial failed to meet the co-primary endpoint of improved PFS with the combination.
At that time, OS data remained immature and the company announced the trial would continue to the next planned analysis.
The overall safety profile of the combination remained consistent with the additional follow-up, according to Genentech. Researchers observed no new safety signals.
Complete data from SKYSCRAPER-01 will be presented at a medical meeting.
Read more about